Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer-Reference-Cited by-同舟云学术

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

Published:2017-04-10 Issue:29 Volume:8 Page:47154-47160
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Rafii Saeed¹,Gourley Charlie²,Kumar Rajiv¹,Geuna Elena¹,Ang Joo Ern¹,Rye Tzyvia²,Chen Lee-May³,Shapira-Frommer Ronnie⁴,Friedlander Michael⁵,Matulonis Ursula⁶,Greve Jacques De⁷,Oza Amit M.⁸,Banerjee Susana⁹,Rhoda Molife L.¹,Gore Martin E.⁹,Kaye Stan B.¹,Yap Timothy A.¹

Affiliation:

1. Drug Development Unit, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK

2. University of Edinburgh Cancer Research UK Centre, Edinburgh, UK

3. University of California San Francisco, San Francisco, CA, USA

4. Sheba Medical Centre, Ramat Gan, Israel

5. Prince of Wales Cancer Centre, Randwick, Australia

6. Dana-Farber Cancer Institute, Boston, MA, USA

7. Oncologisch Centrum UZ Brussel, Brussels, Belgium

8. Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

9. Gynae-Oncology Unit, Royal Marsden Hospital, London, UK

Publisher

Impact Journals, LLC